Neonatal Abstinence Syndrome (NAS) in Southwestern Border States: Examining Trends, Population Correlates, and Implications for Policy

Article
  • 71 Downloads

Abstract

Introduction Neonatal abstinence syndrome (NAS) is withdrawal syndrome in newborns following birth and is primarily caused by maternal drug use during pregnancy. This study examines trends, population correlates, and policy implications of NAS in two Southwest border states. Materials and Methods A cross-sectional analysis of Hospital Inpatient Discharge Data (HIDD) was utilized to examine the incidence of NAS in the Southwest border states of Arizona (AZ) and New Mexico (NM). All inpatient hospital births in AZ and NM from January 1, 2008 through December 31, 2013 with ICD9-CM codes for NAS (779.5), cocaine (760.72), or narcotics (760.75) were extracted. Results During 2008–2013 there were 1472 NAS cases in AZ and 888 in NM. The overall NAS rate during this period was 2.83 per 1000 births (95% CI 2.68–2.97) in AZ and 5.31 (95% CI 4.96–5.66) in NM. NAS rates increased 157% in AZ and 174% in NM. NAS newborns were more likely to have low birth weight, have respiratory distress, more likely to have feeding difficulties, and more likely to be on state Medicaid insurance. AZ border region (border with Mexico) had NAS rates significantly higher than the state rate (4.06 per 1000 births [95% CI 3.68–4.44] vs. 2.83 [95% CI 2.68–2.97], respectively). In NM, the border region rate (2.09 per 1000 births [95% CI 1.48–2.69]) was significantly lower than the state rate (5.31 [95% CI 4.96–5.66]). Conclusions Despite a dramatic increase in the incidence of NAS in the U.S. and, in particular, the Southwest border states of AZ and NM, there is still scant research on the overall incidence of NAS, its assessment in the southwest border, and associated long-term outcomes. The Healthy Border (HB) 2020 binational initiative of the U.S.-Mexico Border Health Commission is an initiative that addresses several public health priorities that not only include chronic and degenerative diseases, infectious diseases, injury prevention, maternal and child health but also mental health and addiction. The growing opioid epidemic and rise in NAS cases in the Southwest border, as partially shown in this study, provides another opportunity to track health illnesses and outcomes in the Southwest border, especially because there are targeted resources through High Intensity Drug Trafficking Areas (HIDTA) funding.

Keywords

Neonatal abstinence syndrome (NAS) LBW Respiratory difficulties Southwest border Border health Disparity Population health 

Notes

Compliance with Ethical Standards

Conflict of interest

The authors have nothing to disclose.

References

  1. Arizona Administrative Code. (2004). Chapter 11 Department of Health Services Health Care Institutions Facility Data; Article 4 Hospital Inpatient Discharge Reporting. Retrieved June 29, 2015 from http://www.azsos.gov/public_services/Title_09/9-11.htm (Archived by WebCite® http://www.webcitation.org/6ZelSQggV).
  2. Arizona Administrative Code. (2004). Chapter 11 Department of Health Services Health Care Institutions Facility Data; Article 5 Emergency Department Discharge Reporting. Retrieved June 29, 2015 from http://www.azsos.gov/public_services/Title_09/9-11.htm. (Archived by WebCite® at http://www.webcitation.org/6ZelSQggV).
  3. Arizona Revised Statues. (2010). Uniform patient reporting system; statistical and demographic reports; exemption. 2010. Retrieved March 10, 2014 from http://www.azleg.state.az.us/FormatDocument.asp?inDoc=/ars/36/00125-05.htm&Title=36&DocType=ARS (Archived by WebCite® at http://www.webcitation.org/6Zeix4UsH).
  4. Bagley, S. M., et al. (2014). Review of the assessment and management of neonatal abstinence syndrome. Addiction Science and Clinical Practice, 9(1), 10.CrossRefGoogle Scholar
  5. Desai, R. J., Hernandez-Diaz, S., Bateman, B. T., & Huybrechts, K. F. (2015a). Increase in prescription opioid use during pregnancy among medicaid-enrolled women. Obstetric Anesthesia Digest, 35, 59–60.CrossRefGoogle Scholar
  6. Desai, R. J., Huybrechts, K. F., Hernandez-Diaz, S., et al. (2015b). Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: Population based cohort study. BMJ, 350, h2102.  https://doi.org/10.1136/bmj.h2102.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Epstein, R. A., Bobo, W. V., Martin, P. R., et al. (2013). Increasing pregnancy-related use of prescribed opioid analgesics. Annals of Epidemiology, 23, 498–503.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Gardner, M. J., & Altman, D. G. (1986). Confidence intervals rather than P Values: Estimation rather than hypothesis testing. British Medical Journal (Clinical Research Edition), 292, 746–750.CrossRefGoogle Scholar
  9. Harrison, L. D., & Kennedy, N. J. (1996). Drug use in the high intensity drug trafficking area of the US Southwest border. Addiction, 91(1), 10.CrossRefGoogle Scholar
  10. Health Information System (HIS) Act. (2015). New Mexico Department of Health. Retrieved September 28, 2015 from http://164.64.110.239/nmac/parts/title07/07.001.0027.htm. (Archived by WebCite® at http://www.webcitation.org/6bsyxWuaJ).
  11. Hussaini, S. K. (2014). Neonatal abstinence syndrome: 2008–2013 overview. Research Brief. Retrieved July 14, 2015 from http://www.azdhs.gov/phs/phstats/documents/neonatal-abstinence-syndrom-research.pdf. (Archived by WebCite® at http://www.webcitation.org/6a1bouZDt).
  12. Jansson, L. M., & Velez, M. (2012). Neonatal abstinence syndrome. Current Opinion in Pediatrics, 24(2), 252–258.  https://doi.org/10.1097/MOP.0b013e32834fdc3a.CrossRefPubMedGoogle Scholar
  13. Ko, J. Y., Patrick, S. W., Tong, V. T., Patel, R., Lind, J. N., & Barfield, W. D. (2016). Incidence of neonatal abstinence syndrome—28 states, 1999–2013. Morbidity and Mortality Weekly Report (MMWR), 65(31), 799–802.CrossRefGoogle Scholar
  14. Logan, B. A., Brown, M. S., & Hayes, M. J. (2013). Neonatal abstinence syndrome: Treatment and pediatric outcomes. Clinical Obstetrics and Gynecology, 56, 186–192.CrossRefPubMedPubMedCentralGoogle Scholar
  15. McDonald, J. A., Argotsinger, B., Mojarro, O., Rochat, R., & Amatya, A. (2015). First trimester initiation of prenatal care in the US-Mexico border region. Medical Care, 53(8), 700–707.  https://doi.org/10.1097/MLR.0000000000000385.CrossRefPubMedGoogle Scholar
  16. McQueen, K., & Murphy-Oikonen, J. (2016). Neonatal abstinence syndrome. New England Journal of Medicine, 375(25), 2468–2479.CrossRefPubMedGoogle Scholar
  17. NM Stat § 24-14A-3 (1996) (1966 through 1st Sess 50th Legis). Retrieved October 9, 2015, from http://law.justia.com/codes/new-mexico/2011/chapter24/article14A/section24-14A-3. (Archived by WebCite® at http://www.webcitation.org/6c9iLtgHz).
  18. Patrick, S. W., Davis, M. M., Lehmann, C. U., & Cooper, W. O. (2015). Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. Journal of Perinatology, 35(8), 650–655.CrossRefPubMedPubMedCentralGoogle Scholar
  19. Patrick, S. W., Schumacher, R. E., Benneyworth, B. D., Krans, E. E., McAllister, J. M., & Davis, M. M. (2012). Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009. JAMA, 307(18), 1934–1940.CrossRefPubMedGoogle Scholar
  20. Tolia, V. N., Patrick, S. W., Bennett, M. M., Murthy, K., Sousa, J., Smith, P. B., et al. (2015). Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. New England Journal of Medicine, 372(22), 2118–2126.CrossRefPubMedGoogle Scholar
  21. U.S. National Library of Medicine. (2012). Neonatal abstinence syndrome. Retrieved September 7, 2012 from http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004566/.
  22. U.S.-Mexico Border Health Commission. (2014). Access to Health Care in the U.S.-Mexico Border Region: Challenges and opportunities, in healthy border 2020.Google Scholar
  23. U.S.-Mexico Border Health Commission. (2015). Healthy border 2020: A prevention and health promotion initiative. Retrieved August 12, 2015 from http://www.borderhealth.org/files/res_2805.pdf. (Archived by WebCite® at http://www.webcitation.org/6ajVSQfdY).
  24. United States Department of Justice. (2011a). Drug Enforcement Agency. New Mexico High Intensity Drug Trafficking Area, Drug Market Analysis 2011. Retrieved October 9, 2015 from http://www.justice.gov/archive/ndic/dmas/New_Mexico_DMA-2011(U).pdf. (Archived by WebCite® at http://www.webcitation.org/6c9f1JuVU).
  25. United States Department of Justice. (2011b). Drug Enforcement Agency. Arizona High Intensity Drug Trafficking Area, Drug Market Analysis 2011. Retrieved September 28, 2015 from http://www.justice.gov/archive/ndic/dmas/Arizona_DMA-2011(U).pdf. (Archived by WebCite® http://www.webcitation.org/6bsuRHMDb).
  26. United States Department of Justice. (2014). Drug Enforcement Agency. National Drug Trafficking Assessment Summary. Retrieved September 28, 2015 from http://www.dea.gov/resource-center/dir-ndta-unclass.pdf/. (Archived by WebCite® http://www.webcitation.org/6bsuNCTVC).
  27. Zingmond, D. S., Parikh, P., Louie, R., et al. (2015). Improving hospital reporting of patient race and ethnicity—approaches to data auditing. Health Services Research, 50, 1372–1389.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Khaleel S. Hussaini
    • 1
  • Luigi F. Garcia Saavedra
    • 2
  1. 1.Department of Biomedical Informatics, College of Medicine PhoenixThe University of ArizonaTucsonUSA
  2. 2.Injury and Behavioral Epidemiology BureauNew Mexico Department of HealthSanta FeUSA

Personalised recommendations